Immune Design Corp (NASDAQ:IMDZ) was up 5.4% during mid-day trading on Friday . The stock traded as high as $4.30 and last traded at $3.90. Approximately 979,400 shares changed hands during trading, an increase of 214% from the average daily volume of 311,582 shares. The stock had previously closed at $3.70.

Several equities research analysts have recently issued reports on IMDZ shares. Wells Fargo & Company cut shares of Immune Design from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $29.00 to $10.00 in a research report on Tuesday, October 17th. ValuEngine cut shares of Immune Design from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 21st. Zacks Investment Research raised shares of Immune Design from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Monday, November 6th. Finally, Royal Bank Of Canada assumed coverage on shares of Immune Design in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $13.19.

Immune Design (NASDAQ:IMDZ) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.11. The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.62 million. Immune Design had a negative net margin of 619.62% and a negative return on equity of 68.69%. sell-side analysts predict that Immune Design Corp will post -1.89 earnings per share for the current fiscal year.

In other news, Director Franklin M. Berger bought 25,000 shares of the stock in a transaction dated Monday, October 30th. The shares were acquired at an average price of $4.58 per share, with a total value of $114,500.00. Following the completion of the acquisition, the director now directly owns 75,000 shares in the company, valued at $343,500. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Leo Guthart bought 10,000 shares of the stock in a transaction dated Thursday, October 19th. The stock was purchased at an average cost of $6.09 per share, for a total transaction of $60,900.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 5,300,000 shares of company stock worth $21,874,900. 20.70% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the company. Victory Capital Management Inc. boosted its holdings in shares of Immune Design by 4.2% in the third quarter. Victory Capital Management Inc. now owns 2,060,234 shares of the biotechnology company’s stock valued at $21,324,000 after acquiring an additional 82,670 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Immune Design by 170.0% during the first quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock worth $760,000 after buying an additional 70,351 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Immune Design by 37.9% during the second quarter. Vanguard Group Inc. now owns 524,999 shares of the biotechnology company’s stock worth $5,118,000 after buying an additional 144,408 shares in the last quarter. Nationwide Fund Advisors boosted its holdings in Immune Design by 1,198.0% during the second quarter. Nationwide Fund Advisors now owns 137,709 shares of the biotechnology company’s stock worth $1,343,000 after buying an additional 127,100 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in Immune Design by 46.9% during the second quarter. Wells Fargo & Company MN now owns 218,700 shares of the biotechnology company’s stock worth $2,132,000 after buying an additional 69,813 shares in the last quarter. 29.38% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/08/immune-design-imdz-trading-up-5-4.html.

About Immune Design

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Stock Ratings for Immune Design Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp and related stocks with our FREE daily email newsletter.